Clinical Trial Update: A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gilteritinib as maintenance therapy after induction/consolidation in adults with FLT3-ITD acute myeloid leukemia in first complete remi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3-itd Mutation

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation | Phase 2 | Status: COMPLETED | Results posted: 2022-06-27